Medi Caps Ltd
Incorporated in 1983, Medi-Caps Ltd is in the business of real estate and pharmaceuticals[1]
- Market Cap ₹ 54.3 Cr.
- Current Price ₹ 43.5
- High / Low ₹ 61.0 / 37.2
- Stock P/E
- Book Value ₹ 97.3
- Dividend Yield 0.00 %
- ROCE -0.68 %
- ROE -0.47 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.45 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -9.97% over past five years.
- Company has a low return on equity of -0.49% over last 3 years.
- Working capital days have increased from 413 days to 716 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
37.49 | 36.11 | 42.97 | 44.04 | 53.70 | 51.79 | 43.05 | 58.72 | 69.87 | 49.37 | 27.35 | 25.47 | |
33.78 | 36.19 | 40.36 | 42.43 | 51.53 | 47.07 | 49.80 | 46.44 | 59.80 | 44.18 | 27.35 | 27.30 | |
Operating Profit | 3.71 | -0.08 | 2.61 | 1.61 | 2.17 | 4.72 | -6.75 | 12.28 | 10.07 | 5.19 | 0.00 | -1.83 |
OPM % | 9.90% | -0.22% | 6.07% | 3.66% | 4.04% | 9.11% | -15.68% | 20.91% | 14.41% | 10.51% | 0.00% | -7.18% |
-1.18 | 1.29 | 0.68 | 2.02 | 1.07 | 2.73 | 2.86 | 0.46 | 1.95 | 1.49 | 0.48 | 2.73 | |
Interest | 1.16 | 0.66 | 0.06 | 0.10 | 0.10 | 0.13 | 0.12 | 0.10 | 0.11 | 0.13 | 0.04 | 0.02 |
Depreciation | 2.07 | 1.81 | 1.80 | 1.81 | 1.79 | 1.82 | 1.83 | 1.52 | 1.81 | 1.74 | 1.69 | 1.72 |
Profit before tax | -0.70 | -1.26 | 1.43 | 1.72 | 1.35 | 5.50 | -5.84 | 11.12 | 10.10 | 4.81 | -1.25 | -0.84 |
Tax % | 155.71% | 63.49% | 39.16% | 20.35% | 14.81% | 2.18% | 0.17% | -0.09% | 0.10% | 63.62% | 80.00% | -32.14% |
-1.79 | -2.06 | 0.86 | 1.37 | 1.15 | 5.39 | -5.85 | 11.13 | 10.08 | 1.76 | -2.24 | -0.57 | |
EPS in Rs | -1.04 | -1.65 | 0.69 | 1.10 | 0.92 | 4.32 | -4.69 | 8.93 | 8.08 | 1.41 | -1.80 | -0.46 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -3% |
5 Years: | -10% |
3 Years: | -29% |
TTM: | -7% |
Compounded Profit Growth | |
---|---|
10 Years: | 6% |
5 Years: | 14% |
3 Years: | % |
TTM: | 77% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 33% |
3 Years: | -4% |
1 Year: | -9% |
Return on Equity | |
---|---|
10 Years: | 2% |
5 Years: | 3% |
3 Years: | 0% |
Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 |
Reserves | 71.00 | 68.94 | 69.80 | 76.62 | 77.75 | 83.13 | 78.48 | 92.24 | 103.79 | 106.10 | 108.51 | 108.81 |
8.87 | 0.81 | 0.08 | 0.09 | 0.17 | 0.12 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
9.60 | 7.00 | 10.68 | 8.19 | 10.52 | 10.89 | 4.20 | 10.11 | 14.09 | 7.42 | 6.31 | 4.14 | |
Total Liabilities | 101.94 | 89.22 | 93.03 | 97.37 | 100.91 | 106.61 | 95.21 | 114.82 | 130.35 | 125.99 | 127.29 | 125.42 |
36.92 | 58.05 | 56.41 | 62.14 | 61.03 | 59.80 | 57.30 | 58.12 | 59.31 | 58.91 | 57.57 | 56.09 | |
CWIP | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.97 | 0.54 | 0.24 | 0.00 | 0.00 | 0.08 |
Investments | 33.72 | 5.43 | 6.74 | 7.83 | 11.18 | 16.35 | 21.97 | 29.41 | 30.67 | 32.07 | 39.46 | 44.12 |
31.20 | 25.74 | 29.88 | 27.40 | 28.70 | 30.46 | 14.97 | 26.75 | 40.13 | 35.01 | 30.26 | 25.13 | |
Total Assets | 101.94 | 89.22 | 93.03 | 97.37 | 100.91 | 106.61 | 95.21 | 114.82 | 130.35 | 125.99 | 127.29 | 125.42 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1.50 | 7.05 | 2.59 | 4.02 | 4.20 | 5.96 | 4.63 | 15.32 | 7.02 | -6.08 | 6.94 | 5.07 | |
1.54 | -6.97 | -1.47 | 2.57 | -4.09 | -5.75 | -5.80 | -9.70 | -4.08 | -2.56 | -7.73 | -4.98 | |
0.00 | 0.00 | -0.73 | -5.76 | 0.08 | -0.05 | -0.06 | -0.06 | 0.00 | 0.00 | 0.00 | 0.00 | |
Net Cash Flow | 0.04 | 0.08 | 0.39 | 0.83 | 0.20 | 0.16 | -1.23 | 5.56 | 2.95 | -8.64 | -0.79 | 0.09 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 111.96 | 87.33 | 82.48 | 74.09 | 88.57 | 90.56 | 37.39 | 39.72 | 52.61 | 62.55 | 144.40 | 125.97 |
Inventory Days | 235.89 | 265.71 | 257.13 | 230.21 | 148.16 | 163.52 | 75.29 | 93.95 | 156.60 | 121.72 | 239.17 | 109.67 |
Days Payable | 52.74 | 66.33 | 101.86 | 75.75 | 90.99 | 96.26 | 26.94 | 86.24 | 154.35 | 48.72 | 76.25 | 54.15 |
Cash Conversion Cycle | 295.12 | 286.71 | 237.75 | 228.56 | 145.73 | 157.82 | 85.74 | 47.42 | 54.85 | 135.55 | 307.32 | 181.49 |
Working Capital Days | 182.65 | 184.07 | 154.26 | 147.11 | 113.51 | 127.85 | 85.21 | 63.96 | 87.66 | 200.50 | 324.16 | 715.53 |
ROCE % | 0.44% | -0.69% | 1.81% | 1.48% | 1.56% | 5.77% | -6.58% | 11.59% | 8.78% | 3.70% | -1.17% | -0.68% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Annual Secretarial Compliance Report filed confirming SEBI regulation adherence, minor past delay rectified.
-
Intimation To The Holders Of Physical Shares In Terms Of SEBI Circular No. SEBI/HO/MIRSD/MIRSD-Pod-1/P/CIR/2023/37 Dated March 16, 2023 Regarding Mandatory Furnishing Of PAN, KYC Details And Nomination.
27 May - Shareholders with physical shares must submit PAN, KYC, bank details, and nomination as per SEBI circulars.
-
Announcement Under Regulation 30 (LODR) Update In U. S. FDA Inspection Of Wholly Owned Subsidiary
24 May - US FDA inspection of Medgel Pvt Ltd classified as VAI; inspection closed with no adverse action.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
23 May - Standalone and consolidated audited financial results for the quarter and year ended 31.03.2025 were approved by the Board in their 01/2025-26 Board meeting held on …
-
Announcement under Regulation 30 (LODR)-Change in Management
21 May - Re-appointment of Praveen Shrivastava & Co. as internal auditor for FY 2025-26.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
MCL operates in real estate as a parent company and pharma division through its wholly owned subsidiary. The company entered the real estate segment for city centric developments by way of Land acquisition and developing premium residential and commercial properties. It has almost completed its first project Medicaps Business Park and also sold ~50% of shops in the project